| Client Services: | 949-340-7598 |
|---|---|
| General & Sales: | 949-472-8000 |
| Study Management: | 949-472-8080 |
Posters & Presentations
| 2020 |
Bristol Myers Squibb and Mosaic Laboratories (Referenced in Methods)Anguiano E, Desai K, Hayati S, Szabo PM, Pant S, Wang L and Zhang N. Comparison of gene expression profiling platforms: Translatability of tumor inflammation gene signatures. AACR Meeting. |
POSTER |
| 2020 |
Celldex and Mosaic Laboratories (Referenced in Methods)Hasanov M, Rioth MJ, Kendra K, Hernandez-Aya L, Joseph RW, Williamson S, Chandra S, Shirai K, Turner CD, Lewis K, Crowley E, Moscow J, Carter B and Patel S. A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. AACR Meeting. |
POSTER |
| 2020 |
Agios and Mosaic Laboratories (Referenced in Methods)Hyer ML, Kalev P, Fletcher M, Chen C-C, Aguado-Fraile E, Mandley E, Newhouse S, Lein M, Nagaraja R, Tuncay Y, Murtie J, Biller SA, Marks KM, Kaya Marjon K. The MAT2A inhibitor AG-270 combines with both taxanes and gemcitabine to yield enhanced antitumor activity in patient-derived xenograft models. AACR Meeting. |
POSTER |
| 2020 |
Agios and Mosaic Laboratories (Referenced in Methods)Lu M, Mellinghoff IK, Diaz A, Taylor JW, Sun, Choe S, Tassinari A, Zhu D, Le K, Tai F, Hassan I, Pandya SS, Steelman L, Wu B. Inhibiting IDH mutations in low-grade glioma alters cellular function and the immune environment. AACR Meeting. |
POSTER |
| 2019 |
Agios Pharmaceuticals and Mosaic Laboratories (Referenced in Methods)Kalev P, Hyer ML, Fletcher M, Zhang P, Aguado-Fraile E, Mandley E, Newhouse S, Tuncay Y, Konteatis Z, TravinsJ, Marks KM and Marjon K. Mitotic Defects Induced by MAT2A Inhibitors Guide Translational Drug Combination Strategies with AG-270 and Taxanes. AACR-NCI-EORTC Meeting. |
POSTER |
| 2019 |
BMS, HTG and Mosaic Laboratories (Referenced in Methods)Szabo PM, Qi Z, Ely S, Edwards R, Lu J, Cooley J, Navratil M, Dalgliesh GL and Adaya N. Association of an Inflammatory Gene Signature with CD8 Expression by Immunohistochemistry in Multiple Tumor Types. ASCO Meeting. |
POSTER |
| 2017 |
Definiens and Mosaic LaboratoriesDauffenbach LM, Kerfoot CA, Sia G, Masci A, Zimmermann J, Lesniak J, Budco A, Lippok S, Schneider K, Korn R, Wiestler T, Medrikova D and Leiß F. Characterization of inflammatory cell patterns and densities using multiplex immunohistochemistry immuno-oncology assays. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. |
POSTER |
| 2017 |
Rexahn and Mosaic LaboratoriesKim DJ, George C, Lee YB, Ahn CH, Frank J, Mazhari R, Dauffenbach LM, Olsen EP Evaluation of UCK2 Protein Expression as a Potential Predictive Biomarker of RX-3117. AACR Meeting. |
POSTER |
| 2017 |
Mosaic LaboratoriesDauffenbach LM, Sia GC, Zheng J, Jun N, Olsen EP, Kerfoot CA. Multiplex Immunohistochemical Staining of PD-L1, PD-1, CD3, CD4, CD8, CD68, FoxP3, and Ki-67 and Image Analysis of Tumor and Invasive Margin in Human FFPE NSCLC Tissue. AACR Meeting. |
POSTER |
| 2017 |
Mosaic LaboratoriesDauffenbach LM, Sia GC, Zheng J, Jun N, Olsen EP, Kerfoot CA. Characterization of M2 Macrophage Subtype Content in Cancer and Normal Tissues. AACR Meeting. |
POSTER |
| 2016 |
BMS and Mosaic Laboratories (Referenced in Acknowledgements)Hussein M, Wilks S, Monte M, Richards DA, Goldschmidt JH, Waterhouse D, Wang L, Yusko E, Emerson R, Taverna DM, Desai K, Mousses S, Qi Z, Hipp JD, Robins H, Kulig K, Batenchuk C. Characterization of the T-Cell Receptor Repertoire in Extensive-Disease Small Cell Lung Cancer. AACR Meeting. |
POSTER |
| 2016 |
3-V Biosciences and Mosaic Laboratories (Referenced in Acknowledgements)O’Farrell M, Heuer T, Grimmer K, Crowley R, Waszczuk J, Fridlib M, Ventura R, Rubio C, Lai J, Panda A, Buckley D, McCulloch W, Kemble G. FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study. AACR Meeting. |
POSTER |
| 2016 |
Celldex and Mosaic Laboratories (Referenced in Methods)Halim A, Bagley RG, Dauffenbach LM, Olsen EP, Keler T. IHC and RT-PCR Assays for Detection of Cancer Antigen NY-ESO-1 in Human Tissues. AACR Meeting. |
POSTER |
| 2016 |
Celldex and Mosaic Laboratories (Referenced under IHC Images)Sanborn RE, Pishvain MJ, Callahan MK, Rizvi N, Kluger H, Yellin M, Rawls T, Vitale L, Halim A, Davis T, Keler T. Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events. AACR Meeting. |
POSTER |
| 2016 |
Celldex and Mosaic Laboratories (Referenced in Methods)Halim A, Bagley RG, Keler T. Glycoprotein NMB (gpNMB) Overexpression is Prevalent in Human Cancers: Pancreatic Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, and Osteosarcoma. AACR Meeting. |
POSTER |
| 2015 |
Mosaic LaboratoriesDauffenbach LM, Sia GC, Cash PA, Girees SK, Lim RS, Zheng J, Olsen EP, Kerfoot CA. Optimization of an Assay for the Detection of PD-L1 by Immunohistochemistry in Formalin-Fixed, Paraffin-Embedded Human Tissue and Cell Lines. AACR Meeting. |
POSTER |
| 2014 |
Mosaic LaboratoriesMcNutt M, Rimm D, Kerfoot CA, Thompson C. Antibody Validation Roundtable: Specificity + Sensitivity + Reproducibility = Validation. Science Webinar. |
PRESENTATION |
| 2014 |
Mosaic LaboratoriesDauffenbach LM, Sia GC, Cash PA, Girees SK, Lim RS, Zheng J, Olsen EP, Richeh R, Kerfoot CA. Optimization of an Assay for the Detection of Phosphorylated FAK by Immunohistochemistry in Formalin-Fixed, Paraffin-Embedded Human Tissue and Cell Lines. AACR Meeting. |
POSTER |
| 2014 |
Mosaic LaboratoriesDauffenbach LM, Sia GC, Cash PA, Girees SK, Lim RS, Zheng J, Olsen EP, Kerfoot CA. Combination of PI3K and MEK Inhibitor Chemosensitivity in Human Tumor Explants and Cell Lines using the Mosaic Blue Assay and Relationship to Biomarkers by Immunohistochemistry. AACR Meeting. |
POSTER |
| 2013 |
Mosaic LaboratoriesDauffenbach LM, Cash PA, Sia GC, Girees SK, Lim RS, Zheng J, Olsen EP, Kerfoot CA. Evaluation of MEK Inhibitor Chemosensitivity in Human Tumor Explants using the Mosaic Blue Assay and Relationship to Biomarkers by Immunohistochemistry. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. |
POSTER |
| 2013 |
Mosaic LaboratoriesDauffenbach LM, Cash PA, Sia GC, Girees SK, Lim RS, Zheng J, Olsen EP, Kerfoot CA. Evaluation of PI3K Inhibitor Chemosensitivity in Human Tumor Explants using the Mosaic Blue Assay™ and Relationship to Biomarkers by Immunohistochemistry. AACR meeting. |
POSTER |
| 2012 |
Bayer Healthcare Pharmaceuticals, Inc. and Mosaic LaboratoriesJeffers M, Dauffenbach LM, Peña C, Lathia C, Bhargava A, Kerfoot CA. Comparison of Commercially Available Phosphorylated ERK Antibodies for Immunohistochemical Biomarker Analysis. AACR meeting. |
POSTER |
| 2012 |
Pathway Therapeutics and Mosaic LaboratoriesO’Farrell M, Ventura R, Tai A, Matthews DJ. The PI3K/mTOR Inhibitor PWT33597 Regresses 786-0 Renal Xenografts. AACR meeting. |
POSTER |
| 2011 |
Daiichi Sankyo and Mosaic LaboratoriesHalim A, Dauffenbach LM, Kerfoot CA, Stull WR, Zwick-Wallasch E, Scheyer R and Senaldi G. Immunohistochemical Analysis of HB-EGF Expression in Breast, Colon, Gastric, Hepatocellular, Lung, Ovarian, Pancreatic and Prostate Cancer. AACR meeting. |
POSTER |
| 2010 |
Merck & Co. and Mosaic LaboratoriesSun A, Lam RL, Pavlick AC, Harman A, Iannone R, Herman G, Dauffenbach LM, Kerfoot CA, Huang P, Bergstrom DA. A Phase 1b Study to Evaluate Induction of pCDC2 in Skin Biopsies from Patients with Solid Tumors Treated with DNA-damaging Chemotherapy. AACR meeting. |
POSTER |
| 2010 |
Mosaic LaboratoriesKerfoot CA , Girees SK and Dauffenbach LM. Multispectral Imaging of Chromogenic Multiplex IHC Assays as an Alternative to Fluorescent Methods. AACR meeting. |
POSTER |
| 2010 |
Bayer Healthcare Pharmaceuticals, Inc., Northeast Bioanalytical Labs and Mosaic LaboratoriesJeffers M, Dauffenbach LM, Bhargava A, Lathia C, Kerfoot CA. Comparison of Commercially Available Phospho-AKT [Ser473] Antibodies for Immunohistochemical Biomarker Analysis. AACR meeting. |
POSTER |
| 2009 |
Ascenta and Mosaic LaboratoriesMacVicar G, Greco FA, Reeves J, Maleski J, Holmlund J, Leopold L. An Open-Label, Multicenter, Phase I/II Study of AT-101 in Combination with Docetaxel and Prednisone in Men with Castrate Resistant Prostate Cancer. ASCO Meeting. |
PRESENTATION |
| 2009 |
Ascenta and Mosaic LaboratoriesPoiesz B, Reeves J, McNulty J, Maleski J, Holmlund J, Leopold L. Preliminary Report of an Open-Label, Multicenter, Phase I/II Study of AT-101 in Combination with Docetaxel and Prednisone in Men with Docetaxel Refractory Prostate Cancer. ASCO Meeting. |
POSTER |
| 2009 |
Ascenta and Mosaic LaboratoriesReeves J, McNulty W, Thomas G, MacVicar G, Maleski J, Leopold L. Preliminary Report of an Open-Label, Multicenter, Phase I/II Study of AT-101 in Combination with Docetaxel and Prednisone in Men with Docetaxel Refractory Prostate Cancer. ASCO Genitourinary Cancers Symposium. |
POSTER |
| 2009 |
Cylene and Mosaic LaboratoriesDrygin D, Bliesath J, Ho C, Siddiqui-Jain A, Streiner N, Chua P, Pierre F, Omori M, O’Brien S, Schwaebe M, Rice WG, Anderes K. Discovery and characterization of CX-4945, a selective orally bioavailable small molecule inhibitor of protein kinase CK2: Phase 1 initiated. AACR Meeting. |
POSTER |
| 2009 |
Cylene and Mosaic LaboratoriesDrygin D, Bliesath J, Ho C, Siddiqui-Jain A, Streiner N, Chua P, Pierre F, Omori M, O’Brien S, Schwaebe M, Rice WG, Anderes K. CX-4945, a small molecule inhibitor of CK2, inhibits angiogenesis by affecting the vascular endothelium and suppressing hypoxia-activated Hif-1α transcription. AACR Meeting. |
POSTER |
| 2009 |
SuperGen and Mosaic LaboratoriesKanekal S, Lei S, and Redkar S. MP-470, a Rad51 Suppressor and Multiple TK Inhibitor, Retards Growth of Primary Human Glioblastoma Multiforma (GBM) Cells and Synergizes E ect of Temozolomide. AACR Meeting. |
POSTER |
| 2009 |
Mosaic LaboratoriesDauffenbach LM, Girees SK, Cash PA, Sia G, Stull WR, Kerfoot CA. Aurora A, pMet, pAKT, and pSTAT3 as predictive and pharmacodynamic biomarkers of EGFR inhibitor response in colon and lung cancer cell lines. AACR Meeting. |
POSTER |
| 2009 |
Mosaic LaboratoriesKerfoot CA. Multiplex Immunohistochemistry and Multispectral Imaging: Expanding the Repertoire for Clinical Trial Monitoring. USCAP Meeting. |
PRESENTATION |
| 2008 |
Mosaic LaboratoriesKerfoot CA, Stull WR, Girees SK, Cash PA, Dauffenbach LM. Mosaic Blue Assay: Erlotinib and gefitinib chemosensitivity in non-small cell lung cancer explants and the relationship to EGFR and other biomarkers. AACR meeting. |
POSTER |
| 2007 |
Mosaic LaboratoriesKerfoot CA , Girees SK, Dauffenbach LM. Multiplex Immunohistochemical characterization of aurora A and aurora B in breast, ovarian, non-small cell lung, and colon cancer. AACR meeting. |
POSTER |
| 2007 |
Mosaic LaboratoriesKerfoot CA and Dauffenbach LM. Quantitative multiplex chromogenic immunohistochemistry. Tucson Symposium. |
POSTER |
| 2006 |
Mosaic LaboratoriesDauffenbach LM and Kerfoot CA. Multiplexing immunohistochemical assays of clinical importance for epidermal growth factor receptor inhibitors. AACR meeting. |
POSTER |
| 2006 |
CRi Inc. and Mosaic LaboratoriesKerfoot CA, Endlich ME, Levenson RM. Multispectral analysis of multiplex immunohistochemical stains. USCAP meeting. |
POSTER |
| 2006 |
CRi Inc. and Mosaic LaboratoriesLevenson RM, Mansfield JR, Kerfoot CA. Multispectral imaging enables double-nuclear and double-membrane immunohistochemistry. International Academy of Pathology Meeting. |
|
| 2006 |
CRi Inc. and Mosaic LaboratoriesMansfield JR, Kerfoot CA, Levenson RM, Multiplexing molecular markers with multispectral imaging. 7th Joint Meeting of the Histochemical Society and the Japan Society of Histochemistry and Cytochemistry. |
POSTER |
| 2006 |
CRi Inc. and Mosaic LaboratoriesMansfield J, Kerfoot CA, Levenson RM. Multiplexing molecular markers with multispectral imaging. Tucson Symposium. |
POSTER |
